Distribution of total net revenues

 

SEK million

2017

2016

2017

2016

 

Oct-Dec

Oct-Dec

Jan-Dec

Jan-Dec

Zubsolv® US

126.5

128.2

485.8

481.8

Zubsolv – Rest of the World

5.6

-

5.6

65.9

Zubsolv – total               

132.1

128.2

491.4

547.7

Abstral® royalties

55.4

52.2

113.2

100.4

Milestone payment Abstral

-

-

-

2.2

Abstral – total

55.4

52.2

113.2

102.6

Edluar® royalties

3.6

4.3

17.3

14.8

OX-CLI

-

-

21.8

40.8

Total

191.0

184.7

643.7

705.9

 Key figures

 

2017

2016

2017

2016

 

Oct-Dec

Oct-Dec

Jan-Dec

Jan-Dec

EBIT margin, %

15.8

18.0

8.9

7.0

Return on shareholder equity, %

8.0

11.0

7.0

10.0

Net debt, SEK million

-8.8

115.4

-8.8

115.4

Debt/equity ratio, %

97.0

128.2

97.0

128.2

Equity/assets ratio, %

32.8

30.0

32.8

30.0

Number of shares, before dilution

34,563,239

34,536,746

34,561,142

34,477,423

Number of shares, after dilution

34,673,802

34,579,512

34,671,706

34,574,337

Earnings per share, before dilution, SEK

0.77

0.97

0.67

0.84

Earnings per share, after dilution, SEK

0.77

0.96

0.67

0.84

Number of employees at the end of the period

90

102

90

102

Shareholders’ equity, SEK million

329.1

310.3

329.1

310.3

Capital employed, SEK million

648.2

708.0

648.2

708.0

Working capital, SEK million

477.5

524.2

477.5

524.2

 Cash flow

 

Cash flow

SEK million

Q4 2017

Q4 2016

Jan - Dec

2017

Jan - Dec

2016

Cash flow from operating activities

-23.0

71.4

146.6

156.2

Investment activities

-0.8

6.7

-1.6

5.5

Financing activities

-26.4

-92.7

-85.4

-90.6

Cash flow (excl exchange rate differences)

-50.2

-14.6

59.6

71.1

Liquid funds

327.9

282.4

327.9

282.4